SCHEMBL30206259

SCHEMBL30206259

CNc1nc(Nc2ccc(N3CCOCC3)cc2)c(C(=O)OC)nc1-c1cccc2c1ncn2C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKMYT1 Q99640 2/20 0.40
▸ EML4 Q9HC35 3/20 0.39
▸ ALK Q9UM73 3/20 0.39
▸ BTK Q06187 3/20 0.39
▸ SYK P43405 1/20 0.38
▸ MAPT P10636 4/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ KDR P35968 1/20 0.38
▸ POLB P06746 1/20 0.37
▸ RET P07949 1/20 0.37
▸ ROS1 P08922 1/20 0.37
▸ FLT3 P36888 1/20 0.37
▸ PIM1 P11309 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29173689 1.00 PKMYT1 (0.40) PKMYT1EML4ALKBTKSYK
SCHEMBL29173508 0.92 PIM1 (0.46) PKMYT1EML4ALKBTKSYK
SCHEMBL29173604 0.92 PTK2 (0.41) PKMYT1ALKBTKMAPTSMN1; SMN2
SCHEMBL30206183 0.92 PTK2 (0.41) PKMYT1ALKBTKMAPTSMN1; SMN2
SCHEMBL30206219 0.92 PIM1 (0.46) PKMYT1EML4ALKBTKSYK
SCHEMBL30206027 0.91 BTK (0.40) PKMYT1BTKMAPTSMN1; SMN2GAA
SCHEMBL30206034 0.91 PKMYT1 (0.40) PKMYT1BTKSYKMAPTSMN1; SMN2
SCHEMBL29173536 0.91 BTK (0.40) PKMYT1BTKMAPTSMN1; SMN2GAA
SCHEMBL29173612 0.91 PKMYT1 (0.40) PKMYT1BTKSYKMAPTSMN1; SMN2
SCHEMBL24944369 0.91 EML4 (0.49) EML4ALKSYKRETROS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PDXK, PGK1, PGK2 PKMYT1 587/4885EML4 2189/4885ALK 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback